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poorer outcome for HER2-positive breast cancer:
indication for personalized therapy
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Yu-Ping Chen4 and Hao Zhang1,2,3*Abstract
Background: Protein Tyrosine Phosphatase Receptor-type O (PTPRO) has recently been in the spotlight as a tumor
suppressor, whose encoding gene is frequently methylated in cancers. We examined the methylation status of the
PTPRO gene promoter in breast cancer and evaluated the correlation between PTPRO promoter methylation and
both clinicopathological parameters and prognosis of breast cancer patients.
Methods: Two hundred twenty-one formalin-fixed, paraffin-embedded (FFPE) tumor tissues, 20 FFPE normal
adjacent tissues and 24 matched plasma samples, collected from primary breast cancer patients, were assessed for
PTPRO gene promoter methylation using methylation-specific PCR. Associations of promoter methylation with
clinicopathological parameters were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models
were used to estimate the effect on survival.
Results: 175 samples gave identifiable PCR products, of which 130 cases (74.3%) had PTPRO gene promoter
methylation. PTPRO methylation correlated with higher histological grade (P = 0.028), but not other clinical
parameters. Multivariate analysis indicated that overall survival (OS) was significantly poorer in HER2-positive, but
not ER-positive patients with methylated-PTPRO. Methylated-PTPRO was detectable in matched plasma samples
and only observed in plasma from patients whose corresponding primary tumors were also methylated.
Conclusions: PTPRO methylation is a common event in the primary breast cancer and can be reliably detected in
peripheral blood samples. PTPRO methylation is associated with poor survival only in HER2-positive patients,
suggesting use of PTPRO methylation as a prognostic factor for breast cancer and for optimizing individualized
therapy for HER2-positive patients.
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As the most common malignancy and the second leading
cause of cancer related deaths in women [1], breast cancer
is a heterogeneous disease with a variety of pathological
entities and varied clinical behavior [2]. The past decade
has brought together substantial advances in comprehen-
sive molecular profiling and a maturation of understand-
ing in tumor biology [3,4]. Such studies provide a more* Correspondence: haozhang@stu.edu.cn
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reproduction in any medium, provided the orprecise molecular stratification of patients and allow us
to better understand the clinical behavior and the targets
for better therapy [5-7]. Despite these improvements,
numerous problems remain. For example, endocrine ther-
apies and newly developed targeted drugs (Trastuzumab
and Lapatinib) provide longer survival, but a number of
patients encounter either de novo or acquired resistance
[8-10]. Furthermore, a fraction of patients suffer severe
adverse events, such as thrombosis and cerebrovascular
or cardiac deaths [11]. Studies on molecular biomarkers
and gene expression signatures for prognostics or therapyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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more factors associated with prognosis, to better person-
alize the choice of management strategies [8].
Protein tyrosine phosphatase receptor-type O (PTPRO),
a type III member of the receptor-type PTP family, has
come to the front as a tumor suppressor in multiple
cancers [12,13]. Its encoding gene is frequently methyl-
ated and suppressed in breast cancer as well as in many
other cancers [14-19]. Recent evidence shows that PTPRO
takes part in estrogen action and has potential in enhan-
cing tamoxifen sensitivity [16]. Furthermore, PTPRO
regulates HER2 signaling and is involved in mammary
morphogenesis; and lower PTPRO expression levels correl-
ate with poor clinical outcome in HER2-positive patients
[20]. These findings add new clues into understanding
the role of PTPRO in breast cancer and signify its clin-
ical prognostic value by indicating a new target for ther-
apy in breast cancer. Nevertheless, to our knowledge
no studies have investigated the prognostic value per se
of PTPRO gene promoter methylation in patients with
primary breast cancer. Therefore, the specific objective
in this study was to better characterize the clinical rele-
vance of PTPRO methylation in breast cancer. To do this,
we determined the methylation status of the PTPRO gene
promoter in 221 Chinese women with sporadic breast
cancer and investigated whether PTPRO methylation was
associated with clinicopathologic parameters and clinical
outcome. In order to access its clinical application poten-
tial as a biomarker in peripheral blood, we further exam-
ined PTPRO in 24 matched plasma samples from breast
cancer patients and 10 plasma samples from a normal
control cohort.
Materials and methods
Human subjects and tissue specimens
A total of 221 breast tissue specimens were harvested and
preserved from patients between June 1998 and December
2010 at the Affiliated Cancer Hospital of Shantou University
Medical College. The median age of the patients was
51 years (range 21–89 years). Among the 221 cases, 123
women were premenopausal and 98 were postmenopausal.
Histologically, all cases were invasive ductal carcinomas. At
the time of operation, 41 cases (18.5%) were grade I tumors,
79 (35.7%) cases were grade II, and 83 cases (37.5%) were
grade III. The pT stage of patients at initial diagnosis was
stage 1 in 12 patients, 2 in 118, 3 in 22, and 4 in 18; in 5
cases the pT stage was not available. The pathological stage
was assessed by surgical clinicians based on pathological
reports and according to the 2003 TNM classification
criteria by the International Union Against Cancer. A
total of 74 cases (48.8%) were lymph node-negative, 41
cases (21.6%) were N1, 43 (10.0%) were N2, and 16 cases
(19.6%) were N3. All patients, unless deceased, were
followed up for at least 15 months and up to 124 months(mean 45.81 ± 17.91). All patients received conventional
postoperative treatments, depending on the extent of the
disease. The patients with ER+/PR + tumors were treated
for 2–5 years with tamoxifen. The outcome was defined
by the months of overall survival (OS) post-surgery. Pre-
operative peripheral blood (5 ml) from each patient was
collected into an EDTA tube for the isolation of plasma.
Control blood samples were obtained from 10 healthy
volunteers. The use of human tissues in this study was ap-
proved by the Academic Committee of Shantou University
Medical College. Patients who died of causes unrelated to
the disease were not included in the study.
Sample processing and genomic DNA bisulfite treatment
Paraffin blocks were cut to 8 μm-thick sections. In order
to avoid cross contamination, a special procedure was
employed in section cutting whereby new blades were
used for each sample, and apparati, such as microtomes
and tweezers, were carefully cleaned and disinfected be-
tween sample processing [21,22]. Two sections were
collected into 1.5-ml microcentrifuge tubes. After xylene
deparaffination and treatment with absolute ethanol, the
sections were digested at 55°C overnight with proteinase
K (0.1 mg/mL) in 200 mL of DNA extraction buffer. Bisul-
fite treatment was then performed with 20 μl of digestion
supernatant, using an EZ DNA Methylation-Direct™ Kit
(Zymo, Beijing) to convert unmethylated cytosine to uracil.
Paraffin blocks of PTPRO-methylated MCF-7 human
cancer cell lines and PTPRO-unmethylated NE-2 immor-
talized normal cell lines were used as positive and negative
controls, respectively, throughout the procedure (includ-
ing FFPE block slicing, DNA extraction, bisulfite modifica-
tion, and methylation-specific PCR).
Blood samples were centrifuged at 3000 × g, and plasma
was carefully transferred into plain polypropylene tubes and
stored at −70°C until further processing. DNA from plasma
samples was extracted using a TIANamp Blood DNA Kit
(TIANGEN, Beijing), following the blood and body fluid
protocol as recommended by the manufacturer (8). The
plasma samples (400 μl/column) were used for DNA
extraction. A final elution volume of 50 μl was used.
DNA (1 μg) from each sample was subjected to bisulfite
modification through the use of an EZ DNA Methylation-
Gold Kit (Zymo Research) following the manufacturer’s
instructions.
PTPRO gene promoter methylation analysis
Methylation-specific PCR (MSP) was performed with
bisulfite-converted genomic DNA isolated from 221 FFPE
specimens, using primers designed by Motiwala [17]:
nonmethylation-specific primers hPTP-UF (5′- ATGTT
TTTGGAGGATTTTGGGT-3′) and hPTP-UR (5′- ATA
CCCCATCACTACACAAACA-3′) and methylation-
specific primers hPTP-MF (5′- CGTTTTTGGAGGATTT









NO % NO %
All 175 130 74.3 45 25.7
Age at diagnosis,
years
<45 56 46 82.1 10 17.9 2.662 0.103
> = 45 119 84 70.6 35 29.4
pT
0-1 12 7 58.3 5 41.7 3.885 0.146
2 118 93 78.8 25 21.2
3-4 40 27 67.5 13 32.5
NA 5 3 2
pN
0 74 51 68.9 23 31.1 7.75 0.051
1 41 27 65.9 14 34.1
2 43 37 86.0 6 14.0
3 16 14 87.5 2 12.5
NA 3 2 1
Clinical stage
I + II 95 68 71.6 27 28.4 1.325 0.25
III 77 61 79.2 16 20.8
NA 3 1 2
Tumor grade
G1 + G2 105 72 68.6 33 31.4 4.481 0.028
G3 67 56 83.6 11 16.4
NA 3 2 1
Estrogen receptor
negative 53 43 81.1 10 18.9 2.432 0.119
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TAACG-3′) amplify 201- and 170-bp products respect-
ively. Thermocycling conditions were modified according
to Motiwala′s method and carried out in a 50-μl reaction
containing ≈ 100 ng of bisulfite-converted DNA, PCR buf-
fer, 10 pmol each of forward and reverse primers, 0.2 mM
dNTPs, and 0.75 units of HotStarTaq® Plus DNA Polymer-
ase (Qiagen, Valencia, CA). After an initial incubation at
94°C for 3 min, a touch-down PCR with 10 cycles of de-
naturation at 94°C for 30 sec, annealing at 55°C (Δ –0.4°C
per cycle) for 1 min (Δ –0.04 sec per cycle), and extension
at 72°C for 30 sec was performed, followed by an additional
35 cycles of denaturation for 30 sec at 94°C, annealing
for 15 sec at 50.4°C, and extension for 30 sec at 72°C.
The reactions ended with a 3 min final extension at 72°C,
and then 10-μl aliquots of the PCR reaction were
subjected to electrophoresis on a 2.5% agarose gel. DNA
was visualized by ethidium bromide staining and cap-
tured by a BioRad Gel Doc™ XR imaging system.
Statistical analyses
The association between methylation status and other
molecular and clinicopathological parameters was calcu-
lated using contingency table methods and tested for sig-
nificance using the chi-square test for categorical variables.
Overall survival curves were calculated using the Kaplan-
Meier method and the log-rank test was used to compare
survival curves. Multivariate analysis was carried out using
the Cox proportional hazard regression with a confidence
interval of 95% to examine whether PTPRO methylation
status was an independent prognostic factor for survival.
All calculations were performed with SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA) for Windows. P-values less
than 0.05 were considered to be statistically significant
(two-sided).Figure 1 Representative MSP assay for PTPRO gene
methylation in FFPE specimens of normal adjacent tissues and
tumors from breast cancer patients. Numbers on top indicate
sample number. NATs, Normal adjacent tissues; Mc, methylated
control, paraffin blocks of MCF-7 human cancer cells; Uc,
unmethylated control, paraffin blocks of NE-2 immortalized normal
cells; M, methylated; U, unmethylated; Mk, DNA markers.
positive 105 73 69.5 32 30.5
NA 17 14 3
Progesterone
receptor
negative 84 66 78.6 18 21.4 2.448 0.118
positive 74 50 67.6 24 32.4
NA 17 14 3
HER2
negative 80 59 73.8 21 26.3 0.009 0.924
positive 78 57 73.1 21 26.9
NA 17 14 3
Menopausal status
premenopausal 94 75 79.8 19 20.2 2.376 0.123
postmenopausal 79 55 69.6 24 30.4
NA 2 0 2
Bold values indicate significance.
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Prevalence of PTPRO methylation in sporadic primary
breast cancer tissues
MSP analysis resulted in an identifiable product in 175
cases. Among these cases, methylation of the PTPRO
promoter was detected in 130 (74.3%) of the 175 tumors.
Among the tumors positive for promoter methylation,
35 (27%) were positive only for the methylated reaction
and 95 (73%) were positive for both the unmethylated
and methylated reactions. For the 20 adjacent normal
tissues, only 1 (5%) displayed the methylation amplicon.
A chi-square test suggested hypermethylation of PTPRO
promoter occurs specifically and frequently in primary
breast cancer (P < 0.000). Figure 1 shows a representative
assay for PTPRO promoter methylation by methylation-
specific PCR.
Correlation of PTPRO methylation with clinicopathologic
parameters
The clinical characteristics of the 175 breast cancer pa-
tients at the time of surgery are summarized in Table 1.
Chi-square testing revealed a statistically significantTable 2 Univariate and multivariate Cox proportional hazards m
Clinicopathological parameters Univariate anal
Hazard ratio CI 95%
Estrogen receptor
positive (vs. negative) 0.737 0.285-1.9
Progesterone receptor
positive (vs. negative) 0.559 0.214-1.4
HER2
positive (vs. negative) 1.765 0.661-4.7
Hormone receptor
positive (vs. negative) 0.737 0.285-1.9
Age
> = 45 (vs. <45) 1.886 0.626-5.6
Histological grade
III (vs. II & I ) 2.572 1.238-5.3
pT
4 & 3 (vs. 2 & 1) 1.724 0.996-2.9
pN
positive (vs. negative) 4.343 1.263-14.9
Stage
III (vs. II & I ) 1.985 0.878-4.4
PTPRO methylation
methylated (vs. unmethylated) 3.273 0.754-14.2
PTPRO methylation & HER2 status
Methylated/HER2+ (vs. others) 2.749 1.065-7.0
3 cases were censored cases before the earliest event in a stratum.
Clinical tumor size and nodal status according to TNM staging system.
Bold values indicate significance. CI, Confidence interval; HER2, human epidermal gassociation between the PTPRO promoter methylation
and tumor grade (P = 0.028), whereas there was no signifi-
cant correlation between PTPRO promoter methylation
and age, pT, pN, stage, ER, PR, HER2 or menopausal sta-
tus. Patients with lymph node metastasis (pN), younger
age, premenopausal status, loss of ER and PR in tumors,
larger tumor size (pT), and advanced stage showed a trend
toward greater hypermethylation, but the trend was not
significant (P = 0.051, 0.103, 0.123, 0.119, 0.118, 0.146,
0.250, respectively).
Prognostic value of breast cancer subtypes determined
by PTPRO methylation status
Using a univariate Cox proportional hazard analysis, we
examined clinicopathologic parameters, PTPRO methy-
lation, and their association with overall survival end
points. As summarized in Table 2, there were trends but
no significant prognostic effects for PTPRO methylation
in the 175 cohorts (HR, 3.273, CI 95%, 0.754-14.209;
P = 0.113). Concerning the biological role of the PTPRO
in the ER pathway and HER2 signaling, we stratified
the entire patient cohort into subpopulations accordingodel for overall survival in breast cancer patients (n = 175)
ysis Multivariate analysis







85 0.052 1.77 1.005-3.118 0.048
33 0.020 4.40 1.238-15.673 0.022
89 0.100
09 0.113
97 0.037 3.663 1.371-9.784 0.010
rowth factor receptor 2.
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unmethylated-PTPRO group did not show a trend for
a more favorable outcome (n = 95; HR, 2.149; CI 95%,
0.463-9.983; P = 0.329). When tumor were HER2-positive,
patients with methylated-PTPRO had a tendency for
poor overall survival compared to those of unmethylated-
PTPRO, but the differences were not significant (n = 78,
HR, 5.112; CI 95%, 0.658-39.723; P = 0.119). Further
analysis according to histological grade could not find
additional significant difference (see Additional file 1:
Figure S1). Kaplan-Meier curves for the above subpopu-
lations according to PTPRO methylation are shown in
Figure 2b, 2c and Additional file 1: Figure S1. These
inconclusive results may be due to the limited sample
size and restricted follow-up period. We then comparedFigure 2 Kaplan-Meier survival curves for overall and stratified subpo
subpopulations in 175 patients according to the categories of PTPRO gene
survival (OS) for all patients, (b) OS for patients with ER-positive patients, (c
patients with PTPRO-methylated/HER2+ tumors and remaining patients ofpatients with combined methylated-PTPRO and HER2-
positivity to the remaining patients in the 175 cohorts
(unmethylated-PTPRO/HER2-positive patients and pa-
tients with HER2-negative tumors irrespective of the
PTPRO methylation status). Significantly higher risk was
observed for the methylated-PTPRO&HER2-positive group
of patients (HR, 2.749, CI 95%, 1.065-7.097; P = 0.037).
To confirm the significance of this finding, we performed
multivariate analysis, treating methylated-PTPRO/HER2-
positivity as a factor with tumor size, lymph node metasta-
sis, histological grade and HER2 status for their impact
on overall survival. After adjustment for these covari-
ates, methylated-PTPRO/HER2-positivity was identified
as an independent predictor for overall survival (HR,
3.663; CI 95%, 1.371-9.784; P = 0.010). Similarly, tumorpulations. Kaplan-Meier survival curves for overall and stratified
promoter methylation status (log-rank test analysis). (a) Overall
) OS for patients with HER2-positive tumors, and (d) OS comparing
the 175 cohorts.
Figure 3 Representative MSP assay for PTPRO gene methylation
detected in matched plasma samples. Numbers on top indicate
sample number. Mc, methylated control; Uc, unmethylated control;
M, methylated; U, unmethylated.
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independent association with overall survival in this
patient cohort. Kaplan-Meier survival curves showed
that promoter methylation of the PTPRO gene plus
HER2-positivity was associated with poor overall sur-
vival (P = 0.029; Figure 2d).
PTPRO methylation as a peripheral blood biomarker for
breast cancer
We further explored the feasibility of detecting PTPRO
methylation in the plasma of matched peripheral bloodTable 3 Methylation patterns of the PTPRO genes in primary
with Clinicopathological parameters
Patient NO. Tumor Plasma HER2
1 ● ● +
2 ● ● +
3 ● ● +
4 ● ● -
5 ● ● -
6 ● ● -
7 ● ● -
8 ● ● -
9 ● ● -
10 ● ● -
11 ● ● -
12 ● ○ +
13 ● ○ +
14 ● ○ +
15 ● ○ -
16 ● ○ -
17 ● ○ -
18 ● ○ -
19 ○ ○ +
20 ○ ○ +
21 ○ ○ -
22 ○ ○ -
23 ○ ○ -
24 ○ ○ -
Methylation ratio (%) 18/24 (75.0) 11/24 (45.8)
●, Methylated; ○, unmethylated.samples from breast cancer patients (Figure 3). Among 24
matched plasma samples, PTPRO was aberrantly methyl-
ated in 11 (45.8%) (Table 3), and detected only in plasma
from patients whose corresponding primary tumors were
also methylated. Additionally, no methylation of PTPRO
was observed in any normal control plasma samples from
10 healthy individuals.
Discussion
A previous study examined 21 breast cancer specimens and
found 17 cases (81%) that had dense hypermethylation in
the CpG island of the PTPRO gene, whereas the adjacent
normal tissue remained unmethylated [16]. We extend
these studies, using a much larger sample size, to show a
similar 74.3% (130/175) incidence of PTPRO methylation
in breast cancer. Our larger sample size enables us to
conclude that the PTPRO methylation is a common
event in primary breast cancer.
Similar to our previous data showing that PTPRO
methylation correlates with advanced stage in esophagealtumors, plasma samples from 24 breast cancer patients
ER PR Age Grade pT pN pM
- - 52 2 2 1 0
- - 49 2 2 0 0
- - 41 2 3 1 0
- - 41 3 2 0 0
+ + 89 3 4 x 0
+ - 58 3 4 2 0
+ - 57 2 4 2 0
+ - 57 1 2 0 0
+ - 54 2 2 0 0
+ + 30 3 3 3 0
- - 48 1 4 2 0
+ + 42 3 4 2 0
- - 52 2 2 0 0
+ + 45 2 4 2 0
+ + 57 2 2 1 0
+ - 62 2 2 2 0
+ + 46 2 4 3 0
+ + 60 3 2 2 0
+ - 42 1 2 1 0
- - 61 3 3 0 0
+ - 36 2 3 3 0
+ + 50 1 1 0 0
+ - 54 3 3 0 0
+ - 54 2 1 0 0
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ation analysis, showing that PTPRO promoter methylation
correlates with tumor histological grade (P = 0.028) suggests
that the PTPRO silencing influences breast cancer differen-
tiation and more directly correlates with aggressive bio-
logical behaviour of tumor. Thus, the precise downstream
effects of PTPRO methylation in the carcinogenesis
and progression of breast cancer deserves further
exploration.
To our knowledge, this is the first report that investi-
gated the prognostic value per se of PTPRO gene pro-
moter methylation in patients with primary breast cancer
[23-26]. Primary survival analysis of the entire cohort
reveals no prognostic value for PTPRO methylation in
breast cancer patients in general. In different stratified
cohort populations, ER-positive patients with unmethylated
PTPRO show statistically insignificant trend toward
more favorable outcome compared to those with meth-
ylated PTPRO. This does not support prior in vitro stud-
ies showing PTPRO enhances tamoxifen sensitivity [16].
If this relationship could be confirmed, ER-positive pa-
tients could be stratified into more precise subpopula-
tions to decide whether the patients need a regimen
containing tamoxifen.
In contrast to the ER-positive group, we first verified that
patients with methylated-PTPRO in the HER2-positive
group have a significantly higher risk for mortality com-
pared to the remaining patients in the cohort. Multivari-
ate analysis identified methylated PTPRO/HER2-positivity
as an independent predictor for overall survival. Our
finding of PTPRO promoter methylation, which would
suppress the PTPRO gene expression, as a cause of poor
survival also explains prior data mining studies showing
low PTPRO expression correlates with poor clinical
prognosis in HER2-positive patients [16,25]. These ob-
servations have major implications for breast cancer
patients with amplified/overexpressed HER2 and unmeth-
ylated PTPRO, targeted drugs therapies (e.g., Trastuzumab
and Lapatinib) may prove ineffective by failing to provide
extensive survival benefits due to active PTPRO. It would
either cut down the costs needed to treat patients or
reduce the risk of side effects caused by target drugs.
To clearly address this question, further studies using
patients of the cohort who receive Trastuzumab ther-
apy are required.
Analysis of matched plasma samples shows that methyl-
ated PTPRO can be utilized as a peripheral tumor bio-
marker for noninvasive diagnosis and disease monitoring.
However, the sensitivity of detection in the plasma fraction
appears to be less than that in tumor tissues [11/18
(61.1%)]. On the other hand, when compared with detec-
tion of expression levels in primary tumor tissue by
RT-PCR or immunohistochemistry, the methylation
approach outlined here has the advantages of ease ofimplementation for either screening of breast cancer in
early stages, or monitoring resistance or relapse [27].
Further validation in a larger series of breast cancer
patients will advance molecular subtyping and enhance
our understanding of the clinical behavior of these
tumors, as well as provide targets for better therapy
[6]. Due to its clinical prognostic value, PTPRO gene
promoter methylation represents a new diagnostic tool to
be added to other clinicopathological and molecular vari-
ables for predicting patients outcome or optimizing indi-
vidualized therapy [28-31].
Conclusions
PTPRO methylation is a common event in primary breast
cancer and can be reliably detected in peripheral blood
samples. PTPRO methylation is associated with unfavor-
able survival in patients with HER2-positive breast tu-
mors, and therefore can serve as a potential prognostic
factor for breast cancer.
Additional file
Additional file 1: Figure S1. Kaplan-Meier survival curves for stratified
subpopulations according to histological grade. Kaplan-Meier survival curves
for overall and stratified subpopulations in 175 patients according to the
categories of PTPRO gene promoter methylation status (log-rank test
analysis). (e) Overall survival (OS) for patients with Grades 1 and 2 tumors, (f)
OS for patients with Grade 3 tumors.
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